HeartBeam

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

HeartBeam reports Q1 loss, eyes FDA clearances for growth

HeartBeam's Q1 2024 performance showed financial challenges but promising technological advancements
The company's focus on FDA clearances and AI development positions it for growth
Opportunities in remote cardiac monitoring and AI-driven healthcare present avenues for expansion
Balancing financial stability with innovation will be key for HeartBeam's future success

HeartBeam advances AIMIGo technology despite financial challenges

HeartBeam is making progress towards FDA clearance for its innovative cardiac monitoring device, AIMIGo.
Despite financial challenges, the company's strong IP protection and AI capabilities position it well for future growth.
Opportunities lie in expanding technology applications, gaining regulatory approval, and leveraging AI for automated diagnostics.

HeartBeam reports Q3 loss, progresses FDA review, and strengthens leadership

HeartBeam's Q3 2024 financials show a net loss of $4.979 million, with a focus on managing cash burn and aligning capital raising with milestones.
The company's core technology and clinical evidence position it well for FDA clearances and commercial launch preparations.
New management appointments bring leadership strength to drive HeartBeam's growth and innovation in cardiac care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights.

HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Branislav Vajdic - Chief Executive Officer & Founder Rob Eno - President Rick Brounstein - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.

HeartBeam, Inc. (BEAT) Q3 2023 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2023 Financial Results.

HeartBeam Reports Third Quarter 2023 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Expansion of Its Scientific Advisory Board.

HeartBeam Announces Expansion of Its Scientific Advisory Board

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias.

HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time.

HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time

Medical device industry veteran, Jon Hunt, will lead the next phase of growth for Implicity as demand for remote cardiac monitoring and data management solutions soars CAMBRIDGE, Mass. , Sept. 27, 2023 /PRNewswire/ -- Implicity , a leader in remote patient monitoring (RPM) and cardiac data management solutions, announced that Jon Hunt, PhD.

Implicity Expands Senior Leadership Team with New U.S. Chief Commercial Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Richa Gujarati and Pooja Chatterjee to Senior Management Team.

HeartBeam Appoints Richa Gujarati and Pooja Chatterjee to Senior Management Team

HeartBeam, Inc. (NASDAQ:BEAT ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder & Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

HeartBeam, Inc. (BEAT) Q2 2023 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2023 Financial Results.

HeartBeam Reports Second Quarter 2023 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Publication of Foundational Study on the Detection of Heart Attacks.

HeartBeam Announces Publication of Foundational Study on the Detection of Heart Attacks

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Deborah Castillo as Vice President of Regulatory Affairs.

HeartBeam Appoints Deborah Castillo as Vice President of Regulatory Affairs

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2023 Results Conference Call on Thursday August 10, 2023 at 4:30 p.m. Eastern Time.

HeartBeam to Host Second Quarter 2023 Results Conference Call on Thursday August 10, 2023 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Dr. Michael R. Jaff to the Board of Directors.

HeartBeam Appoints Dr. Michael R. Jaff to the Board of Directors

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors.

HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced that it has entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired the assets of LIVMOR earlier this year.

HeartBeam Enters into Strategic Alliance Agreement with Samsung

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Automated Cardiac Detection Patent Granted for HeartBeam AIMIGo™ System.

HeartBeam Announces Automated Cardiac Detection Patent Granted for HeartBeam AIMIGo™ System

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces FDA Submission of HeartBeam AIMIGo™ VECG System.

HeartBeam Announces FDA Submission of HeartBeam AIMIGo™ VECG System

HeartBeam, Inc. (NASDAQ:BEAT ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Rob Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James William Sutherland - The Benchmark Company Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam First Quarter 2023 Financial Results Conference Call. At this time all participants are in listen only mode.

HeartBeam, Inc. (BEAT) Q1 2023 Earnings Call Transcript

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2023 Financial Results.

HeartBeam Reports First Quarter 2023 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance.

HeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance

Arqit Quantum Inc

Eve Holding Inc

Early commercial stage companies burn cash as they scale. A rising interest rate environment is a headwind for companies burning cash.

6 Disruptive Stocks That Will Benefit From Interest Rate Policy Change

HeartBeam, Inc. (NASDAQ:BEAT ) Q4 2022 Results Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James William Sutherland - The Benchmark Company Ben Haynor - Alliance Global Partners Operator Greetings. And welcome to the HeartBeam Fourth Quarter and Full-Year 2022 Financial Results Conference Call.

HeartBeam, Inc. (BEAT) Q4 2022 Earnings Call Transcript

cquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System

HeartBeam Reports Fourth Quarter and Full Year 2022 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition extends HeartBeam's reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.

News for HeartBeam Stock (BEAT)